Prehab Prior to Undergoing Tricuspid Intervention

Sponsor
Baylor Research Institute (Other)
Overall Status
Recruiting
CT.gov ID
NCT04665583
Collaborator
(none)
40
1
14.2
2.8

Study Details

Study Description

Brief Summary

This study will aim to standardize the prehabilitation protocol to optimize patients and document the clinical and echo variables that could improve clinical outcomes of tricuspid valve intervention.

Condition or Disease Intervention/Treatment Phase
  • Other: Prehabilitation

Detailed Description

Prior to screening activities, each subject will be given an opportunity to ask questions and to understand the details of study participation. Subjects who meet the inclusion and exclusion criteria and have signed an informed consent form will be considered enrolled into the study. After a subject is consented and enrolled in the study, data will be collected prior to any intervention or surgery at the following time points: a) Screening/Baseline b) Day 1 of Prehab c) Day 2 of Prehab d) Day 3 of Prehab e) Day 4 of Prehab, f) and any data collected immediately prior to an intervention or incision (in the case of a surgical patient)

Subjects meeting eligibility criteria with planned tricuspid intervention will receive in-hospital optimization with THHBP's Prehab Protocol.

Prehabilitation will consist of careful pre-intervention assessment and personalized optimization, guided by Investigator judgment, with a specific focus on right ventricular function. This will be done by using a detailed echo acquisition protocol (Appendix 1). Assessments will be collected according to the schedule of events below (Table 1.). Therapy will include intravenous milrinone therapy and aggressive diuresis with evaluation for clinical and functional signs of improvement, according to standard of care. If there are clinical and functional signs of improvement before Day 4, and the subject is ready for TV surgery or any other intervention, they will have Day 4 procedures performed. After the tests and evaluations are completed, the Principal Investigator or Sub-Investigators will decide if the patient is a candidate for TV surgery or another intervention

Study Design

Study Type:
Observational
Anticipated Enrollment :
40 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Single-Center, Prospective, Open-Label Study Standardizing a Prehabilitation Protocol to Optimize Patients Prior to Undergoing Tricuspid Intervention
Actual Study Start Date :
Oct 25, 2020
Anticipated Primary Completion Date :
Dec 31, 2021
Anticipated Study Completion Date :
Dec 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Prehabilitation

All study patients will receive preoperative optimization with a standardized prehabilitation protocol prior to any intervention.

Other: Prehabilitation
Prehabilitation will consist of careful pre-intervention assessment and personalized optimization, guided by Investigator judgment, with a specific focus on right ventricular function. This will be done by using a detailed echo acquisition protocol (Appendix 1). Assessments will be collected according to the schedule of events below (Table 1.). Therapy will include intravenous milrinone therapy and aggressive diuresis with evaluation for clinical and functional signs of improvement, according to standard of care.

Outcome Measures

Primary Outcome Measures

  1. Change in volume status according to daily input/outputs [4-5 days (Day 1 to Day 4 of Prehab or day of surgical intervention)]

    daily input/outputs (mL)

  2. Change in volume status according to weight [5-6 days (Baseline to Day 4 of Prehab or day of surgical intervention)]

    daily weights (kg)

  3. Change in Severity of Tricuspid Regurgitation by Echocardiographic assessment [5 days (Baseline to Day 4 of Prehab)]

    severity of tricuspid regurgitation (mild, moderate, severe)

  4. Change in Nutritional Status [4 days (Baseline to Day 3 of Prehab)]

    Pre-albumin (mg/dL)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. ≥ 18 years of age

  2. Moderate-Severe or Severe TR

  3. Undergoing tricuspid valve surgical or catheter-based intervention

Exclusion Criteria:
  1. Clinical instability according to the judgement of the Investigator

Contacts and Locations

Locations

Site City State Country Postal Code
1 Baylor Scott & White Heart Hospital - Plano Plano Texas United States 75093

Sponsors and Collaborators

  • Baylor Research Institute

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Baylor Research Institute
ClinicalTrials.gov Identifier:
NCT04665583
Other Study ID Numbers:
  • 020-101
First Posted:
Dec 11, 2020
Last Update Posted:
Jun 10, 2021
Last Verified:
Jun 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 10, 2021